Celltrion Pharm Inc

Chart & Performance

D1W1MN

P/E

41.73

P/S

3.01

EPS

982.50

Div Yield, %

0.50%

Shrs. gr., 5y

0.87%

Rev. gr., 5y

18.09%

Revenues

536.40b

+12.26%

Net income

38.75b

+76.42%

CFO

86.43b

+52.74%

Dividend

Dec 29, 2025200 KRW/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Celltrion Pharm Inc. operates as a South Korean pharmaceutical firm, specializing in the creation and distribution of biosimilar medications and over-the-counter (OTC) drugs. Its extensive product portfolio spans a multitude of therapeutic categories, encompassing treatments for conditions related to liver health, inflammation, allergies, respiratory and cardiovascular systems, digestion, hormonal and metabolic disorders, infectious diseases, immune responses, oncology, and general nutrition. The company supplies its pharmaceutical offerings to a diverse client base, including university hospitals and local pharmacies. Established in 1976, Celltrion Pharm Inc. is based in Cheongju, South Korea.

URL

https://www.celltrionph.com/ko-kr/home/index

IPO date

Feb 03, 2006

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT